Research programme: stem cell therapeutics - Trillium Therapeutics
Latest Information Update: 16 Jun 2014
Price : $50
At a glance
- Originator Stem Cell Therapeutics Corp.
- Developer Trillium Therapeutics Inc
- Mechanism of Action Cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders